Oren Gilad - Mar 28, 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: President, CEO, Director
Signature: /s/ John Hamill, Attorney-in-Fact
Stock symbol: APRE
Transactions as of: Mar 28, 2024
Transactions value $: $0
Form type: 4
Date filed: 3/28/2024, 05:57 PM
Previous filing: Mar 14, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award	$0	+6.73K	+2.07%	$0.00	331K	Mar 28, 2024	Direct	F1
holding	APRE	Common Stock						1.2K	Mar 28, 2024	By daughter	F2
holding	APRE	Common Stock						600	Mar 28, 2024	By son	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Stock Options (Right to Buy)	Award	$0	+26.9K		$0.00	26.9K	Mar 28, 2024	Common Stock	26.9K	$6.69	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2	The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3	Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.